David Berry is a general partner with venture capital firm Flagship Pioneering. In recent years, he has co-founded companies that are developing microbiome products for both human therapeutics and agricultural applications. He spoke with Xconomy during Biotech Week Boston in September about the promise of microbiome medicine and the challenges of developing a new class of drugs.

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski
• Beam Brings In $135M to Turn CRISPR Base Editing into Drugs
• Knock Nabs $10M in Bid to Become the OpenTable of Apartment Leasing